Moneycontrol
Get App
Last Updated : Apr 09, 2020 12:52 PM IST | Source: Moneycontrol.com

Aurobindo Pharma share price jumps 6% on USFDA nod for antidepressant

Aurobindo said this was the first ANDA to be approved out of APL Healthcare formulation facility in Hyderabad.

Q. The Drug controller general of India has allowed restricted use of Kaletra the combination of medications lopinavir and ritonavir, for treating those affected by novel coronavirus after the Indian Council of Medical Research (ICMR) sought an emergency approval for the same. Use of Kaletra was allowed based on the fact that previous studies suggested Kaletra, as effective in preventing SARS from maturing and replicating. It has already achieved good results in China and Japan in curing Coronavirus. What was Lopinavir and Ritonavir originally used for?
Q. The Drug controller general of India has allowed restricted use of Kaletra the combination of medications lopinavir and ritonavir, for treating those affected by novel coronavirus after the Indian Council of Medical Research (ICMR) sought an emergency approval for the same. Use of Kaletra was allowed based on the fact that previous studies suggested Kaletra, as effective in preventing SARS from maturing and replicating. It has already achieved good results in China and Japan in curing Coronavirus. What was Lopinavir and Ritonavir originally used for?
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Aurobindo Pharma share price rallied more than 6 percent intraday on April 9 after the company received approval from the US health regulator for an antidepressant drug.

The stock has gained 58 percent after dropping to Rs 294.7 on March 23, the lowest since May 2014. At 1209 hours, it was quoting at Rs 462.15, up Rs 23.90, or 5.45 percent, on the BSE.

Not only Aurobindo but the entire pharma sector has been buzzing for more than two weeks now.

Close

Aurobindo Pharma had received the final approval from the US Food and Drug Administration (USFDA) to manufacture and market Fluoxetine tablets in 10 mg and 20 mg strengths, the company said in a BSE filing.

Fluoxetine tablets are generic version of Eli Lilly's Prozac' tablets.

The company said the product will be launched in April 2020 and has an estimated market size of $42 million for the 12 months ending February 2020, according to IQVIA.

Fluoxetine is indicated for the acute and maintenance treatment of major depressive disorders in adult patients and in children aged between 8 and 18.

This was the first ANDA to be approved out of APL Healthcare formulation facility in Hyderabad, India, for oral products, it said.

Moneycontrol Ready Reckoner
Now that payment deadlines have been relaxed due to COVID-19, the Moneycontrol Ready Reckoner will help keep your date with insurance premiums, tax-saving investments and EMIs, among others.


Facebook-BCG report suggests these measures for businesses to unlock the changing consumer behaviour in the current pandemic. Read More!

First Published on Apr 9, 2020 12:52 pm
Sections
Follow us on